Frank A Giordano1, Stefanie Brehmer2, Bettina Mürle3, Grit Welzel1, Elena Sperk1, Anke Keller4, Yasser Abo-Madyan1, Elisabeth Scherzinger1, Sven Clausen1, Frank Schneider1, Carsten Herskind1, Martin Glas5, Marcel Seiz-Rosenhagen2, Christoph Groden3, Daniel Hänggi2, Peter Schmiedek2, Bahman Emami6, Luis Souhami7, Kevin Petrecca8, Frederik Wenz1. 1. Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 2. Department of Neurosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 3. Department of Neuroradiology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 4. Clinical Trials Coordination Center of the Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 5. Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Essen, Essen, Germany. 6. Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois. 7. Division of Radiation Oncology, McGill University Health Centre, Montreal, Canada. 8. Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, Canada.
Abstract
BACKGROUND: The median time to recurrence of glioblastoma (GB) following multimodal treatment is ∼7 mo. Nearly all cancers recur locally, suggesting that augmenting local treatments may improve outcomes. OBJECTIVE: To investigate whether intraoperative radiotherapy (IORT) to the resection cavity is safe and effective. METHODS: INTRAGO was a phase I/II trial to evaluate the safety and tolerability of IORT with 20 to 40 Gy of low-energy photons in addition to standard radiochemotherapy (ClinicalTrials.gov ID, NCT02685605). The primary endpoint was safety as per occurrence of dose-limiting toxicities. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). We also performed an exploratory analysis of the local PFS (L-PFS), defined as recurrence within 1 cm of the treated margin. RESULTS: Fifteen patients were treated at 3 dose levels. Of these, 13 underwent incomplete resection, 6 had unresected satellites, and 3 did not receive per-protocol treatment (PPT). The MGMT promoter was unmethylated in 10 patients. The median follow-up was 13.8 mo. The majority of grade 3 to 5 adverse events were deemed unrelated to IORT. Five cases of radionecrosis were observed, 2 were classified as grade 3 events. Other grade 3 events judged related to radiotherapy (external-beam radiotherapy and/or IORT) were wound dehiscence (n = 1), CSF leakage (n = 1), cyst formation (n = 1). No IORT-related deaths occurred. The median PFS was 11.2 mo (95% confidence interval [CI]: 5.4-17.0) for all patients and 11.3 mo (95% CI: 10.9-11.6) for those receiving PPT. The median L-PFS was 14.3 mo (95% CI: 8.4-20.2) for all patients and 17.8 mo (95% CI: 9.7-25.9) for those receiving PPT. The median OS was 16.2 mo (95% CI: 11.1-21.4) for all patients and 17.8 mo (95% CI: 13.9-21.7) for those receiving PPT. CONCLUSION: These data suggest that IORT is associated with manageable toxicity. Considering the limitations of a 15-patient phase I/II trial, further studies aimed at assessing an outcome benefit are warranted.
BACKGROUND: The median time to recurrence of glioblastoma (GB) following multimodal treatment is ∼7 mo. Nearly all cancers recur locally, suggesting that augmenting local treatments may improve outcomes. OBJECTIVE: To investigate whether intraoperative radiotherapy (IORT) to the resection cavity is safe and effective. METHODS: INTRAGO was a phase I/II trial to evaluate the safety and tolerability of IORT with 20 to 40 Gy of low-energy photons in addition to standard radiochemotherapy (ClinicalTrials.gov ID, NCT02685605). The primary endpoint was safety as per occurrence of dose-limiting toxicities. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). We also performed an exploratory analysis of the local PFS (L-PFS), defined as recurrence within 1 cm of the treated margin. RESULTS: Fifteen patients were treated at 3 dose levels. Of these, 13 underwent incomplete resection, 6 had unresected satellites, and 3 did not receive per-protocol treatment (PPT). The MGMT promoter was unmethylated in 10 patients. The median follow-up was 13.8 mo. The majority of grade 3 to 5 adverse events were deemed unrelated to IORT. Five cases of radionecrosis were observed, 2 were classified as grade 3 events. Other grade 3 events judged related to radiotherapy (external-beam radiotherapy and/or IORT) were wound dehiscence (n = 1), CSF leakage (n = 1), cyst formation (n = 1). No IORT-related deaths occurred. The median PFS was 11.2 mo (95% confidence interval [CI]: 5.4-17.0) for all patients and 11.3 mo (95% CI: 10.9-11.6) for those receiving PPT. The median L-PFS was 14.3 mo (95% CI: 8.4-20.2) for all patients and 17.8 mo (95% CI: 9.7-25.9) for those receiving PPT. The median OS was 16.2 mo (95% CI: 11.1-21.4) for all patients and 17.8 mo (95% CI: 13.9-21.7) for those receiving PPT. CONCLUSION: These data suggest that IORT is associated with manageable toxicity. Considering the limitations of a 15-patient phase I/II trial, further studies aimed at assessing an outcome benefit are warranted.
Authors: K Steininger; K H Kahl; I Konietzko; C Wolfert; S Motov; P E Krauß; T Bröcheler; M Hadrawa; B Sommer; G Stüben; E Shiban Journal: Neurosurg Rev Date: 2022-07-26 Impact factor: 2.800
Authors: Dilini S Pinnaduwage; Shiv P Srivastava; Xiangsheng Yan; Shyam Jani; David G Brachman; Stephen P Sorensen Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec
Authors: Arne Mathias Ruder; Laurens Inghelram; Frank Schneider; Gustavo R Sarria; Jürgen Hesser; Frederic Bludau; Udo Obertacke; Frederik Wenz; Yasser Abo-Madyan; Frank A Giordano Journal: J Contemp Brachytherapy Date: 2020-10-30
Authors: Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin Journal: J Neurooncol Date: 2019-11-19 Impact factor: 4.130
Authors: Christopher P Cifarelli; Stefanie Brehmer; John Austin Vargo; Joshua D Hack; Klaus Henning Kahl; Gustavo Sarria-Vargas; Frank A Giordano Journal: J Neurooncol Date: 2019-10-25 Impact factor: 4.130
Authors: Gustavo R Sarria; Zuzanna Smalec; Thomas Muedder; Jasmin A Holz; Davide Scafa; David Koch; Stephan Garbe; Matthias Schneider; Motaz Hamed; Hartmut Vatter; Ulrich Herrlinger; Frank A Giordano; Leonard Christopher Schmeel Journal: Front Oncol Date: 2021-10-28 Impact factor: 6.244
Authors: Gustavo R Sarria; Vera Petrova; Frederik Wenz; Yasser Abo-Madyan; Elena Sperk; Frank A Giordano Journal: Radiat Oncol Date: 2020-05-14 Impact factor: 3.481
Authors: Motaz Hamed; Anna-Laura Potthoff; Julian P Layer; David Koch; Valeri Borger; Muriel Heimann; Davide Scafa; Gustavo R Sarria; Jasmin A Holz; Frederic Carsten Schmeel; Alexander Radbruch; Erdem Güresir; Niklas Schäfer; Patrick Schuss; Stephan Garbe; Frank A Giordano; Ulrich Herrlinger; Hartmut Vatter; Leonard Christopher Schmeel; Matthias Schneider Journal: Cancers (Basel) Date: 2022-03-16 Impact factor: 6.639